Question 1

Which enrichment strategy should a project adopt?

Accepted Answer

Marker-based capture gives high purity but misses cells that have reduced epithelial marker expression. Physical separation by size or deformability is marker-independent yet recovers more background. Leucocyte depletion keeps everything else including unusual populations, at the cost of a larger sample to review. Many projects combine two approaches.

Question 2

How should target cells be defined for counting?

Accepted Answer

Write explicit criteria before scoring: which markers must be present, which leucocyte markers must be absent, whether an intact nucleus is required, and what size or morphology limits apply. Counts differ substantially between criteria, so a study without stated rules cannot be compared with any other.

Question 3

How is recovery validated realistically?

Accepted Answer

Spike known numbers of labelled cells into blood from donors without cancer across a range spanning very low counts, and process them exactly as clinical samples. Report recovery with variability at the lowest concentration. Note that cultured cells survive processing better than patient cells, so field recovery is usually lower.

Question 4

Why does preanalytical handling matter so much?

Accepted Answer

Target cells are fragile and decline quickly in standard tubes, so preservative tubes, time to processing and storage temperature all change yield. Fix these variables across the whole cohort and record them per sample, because a difference between study groups in processing delay can produce an apparent biological finding.

Question 5

What limits single-cell molecular analysis here?

Accepted Answer

Input material is minimal, so whole-genome or transcriptome amplification introduces uneven coverage and errors that mimic real variation. Include single leucocytes as negative controls and cells of known genotype as positive controls in every batch, and confirm key findings by an independent method before drawing conclusions.

Question 6

How do these cells compare with circulating tumour DNA?

Accepted Answer

Fragmented DNA is easier to recover and suits mutation tracking, but it cannot report protein expression, morphology or viability, and it gives no intact cell for functional study. Whole cells allow phenotype, single-cell heterogeneity and culture attempts. The two are complementary, and studies increasingly report both.

Question 7

What design supports a clinical correlation claim?

Accepted Answer

Prespecify the threshold and the endpoint before analysis, collect samples at fixed timepoints relative to treatment, and have enumeration performed blinded to clinical status. Report how many samples failed processing, since selective exclusion of difficult samples inflates apparent association with outcome.

Biotechnology

Biotechnology

Research Frontiers in Circulating Tumor Cell Analysis